{"transactions":[{"id":706955,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-07-17T20:05:04.000Z","date":"2026-07-16","kind":"sale","planned":false,"acquired":false,"shares":9500,"price":23.1809,"value":220218.55,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.18 to $23.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":585038,"source":{"system":"sec-edgar","filing":"0001193125-26-307791","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526307791/ownership.xml","form_type":"4"}},{"id":755091,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-02T20:05:24.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":468,"price":19.7262,"value":9231.8616,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.69 to $19.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":594538,"source":{"system":"sec-edgar","filing":"0001193125-26-253472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526253472/ownership.xml","form_type":"4"}},{"id":755090,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-02T20:05:24.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":4998,"price":19.412,"value":97021.176,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.69 to $19.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":595006,"source":{"system":"sec-edgar","filing":"0001193125-26-253472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526253472/ownership.xml","form_type":"4"}},{"id":791862,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-05-05T20:05:03.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":5467,"price":18.922,"value":103446.574,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.67 to $19.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":600004,"source":{"system":"sec-edgar","filing":"0001193125-26-206344","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526206344/ownership.xml","form_type":"4"}},{"id":808216,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-04-15T20:05:02.000Z","date":"2026-04-14","kind":"sale","planned":false,"acquired":false,"shares":8000,"price":17.6406,"value":141124.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.64 to $17.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":605471,"source":{"system":"sec-edgar","filing":"0001193125-26-156981","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526156981/ownership.xml","form_type":"4"}},{"id":861913,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-03-04T21:50:05.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":5466,"price":17.9243,"value":97974.2238,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50 to $18.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":613471,"source":{"system":"sec-edgar","filing":"0001193125-26-091733","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526091733/ownership.xml","form_type":"4"}},{"id":942268,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-09T21:05:17.000Z","date":"2026-01-07","kind":"sale","planned":true,"acquired":false,"shares":309,"price":24.5736,"value":7593.2424,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.43 to $24.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":618937,"source":{"system":"sec-edgar","filing":"0001193125-26-008902","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526008902/ownership.xml","form_type":"4"}},{"id":942267,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-09T21:05:17.000Z","date":"2026-01-07","kind":"sale","planned":true,"acquired":false,"shares":1450,"price":23.8762,"value":34620.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.43 to $24.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":619246,"source":{"system":"sec-edgar","filing":"0001193125-26-008902","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526008902/ownership.xml","form_type":"4"}},{"id":942266,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-09T21:05:17.000Z","date":"2026-01-07","kind":"sale","planned":true,"acquired":false,"shares":3707,"price":23.2422,"value":86158.8354,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.42 to $23.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":620696,"source":{"system":"sec-edgar","filing":"0001193125-26-008902","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526008902/ownership.xml","form_type":"4"}},{"id":951855,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:04:37.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":406000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of this option shall vest and become exercisable on January 2, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":406000,"derivative":{"exercise_price":15.31,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":406000},"source":{"system":"sec-edgar","filing":"0001193125-26-002389","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526002389/ownership.xml","form_type":"4"}},{"id":951854,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-05T21:04:37.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":10135,"price":15.17,"value":153747.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.17 to $15.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":624403,"source":{"system":"sec-edgar","filing":"0001193125-26-002389","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526002389/ownership.xml","form_type":"4"}},{"id":951853,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-05T21:04:37.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 2, 2027, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":634538,"source":{"system":"sec-edgar","filing":"0001193125-26-002389","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526002389/ownership.xml","form_type":"4"}},{"id":1311007,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-06T21:15:09.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":575000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest and become exercisable on January 1, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":575000,"derivative":{"exercise_price":7.11,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":575000},"source":{"system":"sec-edgar","filing":"0000950170-25-002100","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000095017025002100/ownership.xml","form_type":"4"}},{"id":1311006,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-01-06T21:15:09.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":128000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 1, 2026, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 1, 2026, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":544538,"source":{"system":"sec-edgar","filing":"0000950170-25-002100","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000095017025002100/ownership.xml","form_type":"4"}},{"id":1688272,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-04T21:15:42.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":346000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":346000,"derivative":{"exercise_price":5.71,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":346000},"source":{"system":"sec-edgar","filing":"0001209191-24-000767","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000120919124000767/doc4.xml","form_type":"4"}},{"id":2068474,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-04T21:31:13.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":472000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":472000,"derivative":{"exercise_price":7.78,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":472000},"source":{"system":"sec-edgar","filing":"0001209191-23-000956","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000120919123000956/doc4.xml","form_type":"4"}},{"id":2361302,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-02T23:26:59.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":315600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":315600,"derivative":{"exercise_price":13.41,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":315600},"source":{"system":"sec-edgar","filing":"0000899243-22-008673","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000089924322008673/doc4.xml","form_type":"4"}},{"id":2655030,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-25T21:00:47.000Z","date":"2021-06-23","kind":"grant","acquired":true,"shares":141623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of this option shall vest and become exercisable on May 28, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":141623,"derivative":{"exercise_price":19,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":141623},"source":{"system":"sec-edgar","filing":"0000899243-21-025976","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000089924321025976/doc4.xml","form_type":"4"}},{"id":2655029,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-25T21:00:47.000Z","date":"2021-04-12","kind":"grant","acquired":true,"shares":538517,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the \"Reverse Split\"). This amount has been adjusted to give effect to the Reverse Split."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F1","text":"On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the \"Reverse Split\"). This amount has been adjusted to give effect to the Reverse Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of this option shall vest and become exercisable on April 9, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the \"Reverse Split\"). This amount has been adjusted to give effect to the Reverse Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the \"Reverse Split\"). This amount has been adjusted to give effect to the Reverse Split."}],"balance_after":538517,"derivative":{"exercise_price":6.14,"expiration_date":"2031-04-12","underlying":"Common Stock","underlying_shares":538517},"source":{"system":"sec-edgar","filing":"0000899243-21-025976","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000089924321025976/doc4.xml","form_type":"4"}}]}